TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| WellPoint CEO Is Grilled Pressure is mounting on WellPoint Chief Executive Angela Braly, who faced tough questions about the health insurer's practices before its annual meeting ended abruptly Tuesday. online.wsj.com |
Biotech: Update on Deals, Mergers, Funding The Burrill Report submits: By Marie DaghlianNutritional supplements may have passed their media heyday but they are still big business. This week private equity firm The Carlyle Group decided to beef up its portfolio by acquiring NBTY (NTY), a global nutritional supplements company that markets products under the names Nature's Bounty, Vitamin World, and Puritan's Pride, in a transaction valued at $3.8 billion. Carlyle, which has assets of more than $90.5 billion under management, will pay $55 per share in cash for all outstanding common shares of NBTY, representing a premium of approximately 57 percent over NBTY's average closing share price during the 30 trading days ended July 14, 2010. The transaction is expected to close by the end of 2010. The announcement triggered a 43 percent jump in NBTY’s shares to $53.74. Complete Story » seekingalpha.com |
Vote Sets Up Health-Plan Challenges Opponents of the Obama administration's health-care overhaul say Missouri voters' rejection of a key plank could re-energize the push in other states to challenge it. online.wsj.com |
Bullish Trends at Keryx Biopharmaceuticals M.E. Garza submits: Shares of Keryx Biopharmaceuticals (Nasdaq: KERX) have started to trade higher and a Bullish flow has been detected in KERX with 6494 calls trading, or 5x the recent average daily call volume. Options traders are obviously placing their bets that this stock is headed higher.The emerging biopharma has two lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA and the stock price is rising ahead of the Phase 3 developments for Zerenex, which are due in December. Zerenex is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Complete Story » seekingalpha.com |
PPD Earns 2010 Site Solutions Summit Eagle Award [Business Wire] - PPD, Inc. today announced it has been named the recipient of the 2010 Site Solutions Summit Eagle Award, recognizing the company as the most desirable contract research organization with which to partner in an independent study of more than 300 experienced investigative sites. us.rd.yahoo.com |